相关实验视频

Updated: Mar 3, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

[使用阿斯的向阿尔法疗法的临床应用]

Tadashi Watabe¹

¹Graduate School of Medicine, The University of Osaka.

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

|March 1, 2026

概括

使用astatine-211的向阿尔法疗法在治疗晚期甲状腺癌方面表现有前途. 首次在人身上进行的试验证明了临床疗效,目前正在进行的研究正在探索其对其他癌症的潜力.

科学领域:

核医学是一种核医学.
在瘤学瘤学.
放射化学放射化学是指辐射化学.

背景情况:

向性阿尔法疗法 (TAT) 与β-发射体疗法相比,具有更高的疗效.
阿斯-211 (Astatine-211 (²¹¹At)) 是TAT的一个有前途的α发射剂,可以通过循环仪产生.
阿斯与的化学相似性有助于其被甲状腺癌细胞吸收.

研究的目的:

为了评估²¹¹标记的甲酸 (NaAt) 在转移性甲状腺癌患者的临床疗效和安全性.
探索开发用于各种癌症的新211基放射性药物.

主要方法:

在放射性耐药的转移性甲状腺癌患者中进行了第一个使用NaAt的人类临床试验.
开发并临床前评估了针对前列腺特异性膜抗原 (PSMA) 的标记化合物.
积极开发泛瘤向探针,包括LAT1和EphA2向剂.

主要成果:

在接受治疗的患者中观察到激性病变的消失.
报告了血清甲状腺蛋白水平的显著降低,表明瘤反应.
临床前研究显示,At-PSMA和其他新型药物具有前景.

结论:

基于AT的向阿尔法疗法显示出治疗转移性甲状腺癌的巨大潜力.
随着各种放射性药物的持续开发,可能会扩大瘤学中的应用.
阿斯-211对未来的癌症治疗策略有着革命性的前景.

关键词:

亚斯泰因 (211At) 是一种亚斯泰因.前列腺癌是前列腺癌.前列腺特异性膜抗原 (PSMA)亚酸 (NaAt) 是一种酸.甲状腺癌是一种癌症.

更多相关视频

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...